Skip to content
‹ Back to IndustriesSciences

Optical Biosensors Are Increasingly Used at Point-of-Care and in Medical Laboratories

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Promoted Content
Share
Optical Biosensors Are Increasingly Used at Point-of-Care and in Medical Laboratories

Key takeaways

01

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories.

02

One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood.

03

In addition, before this technology, many analyses had to be performed using large equipment located in central…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central laboratories, causing delays in diagnosis. Let’s take a look at the future of optical sensing at point-of-care and in medical laboratories.

Biosensors Are Used in a Wide Variety of Applications

Simply put, a biosensor is a self-contained analytical device combining a biological element with a physicochemical component to generate a measurable signal for further analysis. In recent years, biosensors have become more widely used in medical diagnostics and biotechnology, as well as in pharmaceuticals, food, beverage, environmental, and agricultural industries. This is due to their simplicity in operation, higher sensitivity, ability to perform multiplex analysis, and capability to be integrated with different functions by the same computer chip.

Biosensors are highly responsive, making them ideal for sensing real-time signals from the production of biomolecules. Blood glucose monitoring is one of the most popular applications of biosensors in recent years. Also, biosensors are used in clinical laboratories to detect lactate, peroxides, and cytokines, as well as the release of proteins or antibodies in different inflammatory diseases and tumors.

New Biosensor Technology Will Lead to Increased Adoption

Since the development of the first oxygen biosensor in 1962, there have been enormous strides in biosensor technology. Even so, the practical application of biosensors in the field of medicine is still in its infancy. Further growth will be driven by the creation of devices that are able to provide results at or near the patient efficiently.

In order to increase their adoption, these devices need further advancement regarding simplicity, sensitivity, multiplex analysis of multiple biomarkers, and integration of different functions by the same computer chip. This will allow non-laboratory personnel like nurses and respiratory therapists to perform testing directly at point-of-care. Additionally, in-house laboratories will gain the greater capability to perform more sophisticated testing that once had to outsourced to large industrial laboratories. This will result in more rapid turnaround times for test results, reduced costs, and higher patient satisfaction.

Fiberguide is Helping to Drive the Advancement of Biosensors

For biosensors to become more powerful and user-friendly, there must be continuous development in optical fiber technology. Fiberguide manufactures over 500 different specialty optical fibers packaged in a variety of assemblies and bundles for optical power delivery and optical sensing applications. Fiberguide has proved their commitment to reliable, long-term, strategic partnerships with OEM manufacturers, providing efficient, cost-effective, practical fiber optic solutions engineered to meet specific needs.

Read more at fiberguide.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512